The invention belongs to the technical field of
biology, and particularly relates to an adeno-associated
virus vector for targeting cardiac
vascular endothelium and an application of the adeno-associated
virus vector. The invention aims to solve the problem that natural AAV has poor cardiovascular endothelial transduction capacity
in vivo. The invention provides an adeno-associated
virus vector targeting heart
vascular endothelium. The
library is constructed by inserting an R588 site of an AAV2
capsid protein gene into a coding sequence of random heptapeptide, and inserting the coding sequenceinto a
plasmid skeleton containing an AAV2 rep
gene and ITR through
HindIII / NotI double
enzyme digestion. After two rounds of in-vivo
directed evolution screening, the two AAV variants EC71 and EC73are obtained, the transduction capacity of AAV to the heart
vascular endothelium in vivo is improved, meanwhile, transduction to the liver is greatly reduced, and transgenic expression is maintained for at least four months in the
mouse heart vascular
endothelium. The EC71 vector is used for conveying the eNOS
gene into a
myocardial infarction mouse body, so that the activity of the eNOS
protein of the heart and the
lung is effectively improved, and the EC71 vector has a certain application prospect in gene therapy of cardiovascular endothelial related diseases.